Related Experiment Videos
Propranolol concentrations in plasma after insertion into the vagina
British Medical Journal (Clinical Research Ed.)
|October 29, 1983
Summary
Vaginal administration of propranolol resulted in higher plasma concentrations compared to oral dosing. While minor physiological changes occurred, no symptomatic side effects were reported, suggesting potential for vaginal drug delivery.
Area of Science:
- Pharmacokinetics
- Reproductive Health
Background:
- Propranolol is a beta-blocker medication.
- Vaginal drug delivery offers potential for localized or systemic effects.
- Understanding propranolol's pharmacokinetic profile via vaginal administration is crucial.
Purpose of the Study:
- To determine plasma concentrations of propranolol after vaginal administration.
- To compare vaginal versus oral propranolol pharmacokinetics.
- To assess physiological effects and tolerability of vaginal propranolol.
Main Methods:
- Six healthy women received vaginal propranolol.
- Plasma concentrations were measured over time.
- Four participants also received oral propranolol for comparison.
- Systolic blood pressure, pulse rate, and forced expiratory volume were monitored.
Main Results:
- Area under the concentration-time curve was significantly greater for vaginal propranolol compared to oral.
- Minor reductions in systolic blood pressure, pulse rate, and FEV1 were observed post-vaginal administration.
- No symptomatic side effects were reported.
Conclusions:
- Vaginal administration of propranolol leads to higher systemic exposure than oral dosing.
- The vagina demonstrates tolerability to propranolol, but further safety and efficacy studies are needed.
- Future research on contraceptive effects should utilize the dextro isomer of propranolol.